Hemostemix Inc. (CVE:HEM – Get Free Report)’s share price shot up 31% during trading on Thursday . The company traded as high as C$0.24 and last traded at C$0.19. 727,200 shares traded hands during mid-day trading, an increase of 59% from the average session volume of 456,000 shares. The stock had previously closed at C$0.15.
Hemostemix Stock Performance
The company has a market capitalization of C$20.91 million, a PE ratio of -12.00 and a beta of 0.20. The business has a fifty day moving average price of C$0.09 and a 200 day moving average price of C$0.07.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Stories
- Five stocks we like better than Hemostemix
- Consumer Discretionary Stocks Explained
- Driving Forward: Lucid’s Growing Sales and Gravity SUV’s Impact
- Do ETFs Pay Dividends? What You Need to Know
- Why Amazon’s Next Earnings Could Trigger a Stock Breakout
- How to Use the MarketBeat Excel Dividend Calculator
- With This Kind of Data, The Fed Isn’t Cutting Rates This Year
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
